These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 21864263

  • 1. Anti-TNF treatment in rheumatoid arthritis.
    Geiler J, Buch M, McDermott MF.
    Curr Pharm Des; 2011; 17(29):3141-54. PubMed ID: 21864263
    [Abstract] [Full Text] [Related]

  • 2. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
    Sung YK, Cho SK, Kim D, Won S, Choi CB, Bang SY, Hong SJ, Kim HA, Koh EM, Lee HS, Suh CH, Yoo DH, Bae SC.
    Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ, Curiale C, Petersel D, Rolland C, Jones H, Mysler E.
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [Abstract] [Full Text] [Related]

  • 4. Etanercept for the treatment of rheumatoid arthritis.
    Zhao S, Mysler E, Moots RJ.
    Immunotherapy; 2018 Mar 01; 10(6):433-445. PubMed ID: 29482402
    [Abstract] [Full Text] [Related]

  • 5. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F.
    Recenti Prog Med; 2003 Sep 01; 94(9):361-79. PubMed ID: 12942798
    [Abstract] [Full Text] [Related]

  • 6. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
    Braun J, Kay J.
    Expert Opin Drug Saf; 2017 Mar 01; 16(3):289-302. PubMed ID: 28068848
    [Abstract] [Full Text] [Related]

  • 7. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec 01; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 8. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
    Kita J, Tamai M, Arima K, Nakashima Y, Suzuki T, Kawashiri SY, Okada A, Koga T, Yamasaki S, Nakamura H, Origuchi T, Aramaki T, Nakashima M, Fujikawa K, Tsukada T, Ida H, Aoyagi K, Uetani M, Eguchi K, Kawakami A.
    Mod Rheumatol; 2012 Apr 01; 22(2):195-201. PubMed ID: 21898075
    [Abstract] [Full Text] [Related]

  • 9. Advances in rheumatoid arthritis.
    Jones G, Nash P, Hall S.
    Med J Aust; 2017 Mar 20; 206(5):221-224. PubMed ID: 28301793
    [Abstract] [Full Text] [Related]

  • 10. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F, Anelli MG, Rinaldi A, Serafino L, Covelli M, Scioscia C, Iannone F, Lapadula G.
    Drug Dev Res; 2014 Nov 20; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [Abstract] [Full Text] [Related]

  • 11. Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review.
    Liang SJ, Zheng QY, Yang YL, Yang Y, Liu CY.
    Rheumatol Int; 2017 Jul 20; 37(7):1207-1212. PubMed ID: 28255643
    [Abstract] [Full Text] [Related]

  • 12. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Aug 20; 54(8):2368-76. PubMed ID: 16868999
    [Abstract] [Full Text] [Related]

  • 13. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis.
    Komaki Y, Yamada A, Komaki F, Kudaravalli P, Micic D, Ido A, Sakuraba A.
    J Autoimmun; 2017 May 20; 79():4-16. PubMed ID: 28209290
    [Abstract] [Full Text] [Related]

  • 14. Rheumatoid arthritis: new monoclonal antibodies.
    Serio I, Tovoli F.
    Drugs Today (Barc); 2018 Mar 20; 54(3):219-230. PubMed ID: 29771256
    [Abstract] [Full Text] [Related]

  • 15. The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.
    Hernández MV, Sanmartí R, Cañete JD.
    Expert Opin Drug Saf; 2016 May 20; 15(5):613-24. PubMed ID: 26927029
    [Abstract] [Full Text] [Related]

  • 16. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.
    Woodworth TG, den Broeder AA.
    Best Pract Res Clin Rheumatol; 2015 May 20; 29(4-5):543-9. PubMed ID: 26697765
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis.
    Mok CC, Tsai WC, Chen DY, Wei JC.
    Expert Opin Biol Ther; 2016 May 20; 16(2):201-11. PubMed ID: 26560845
    [Abstract] [Full Text] [Related]

  • 18. Non-TNF biologics and their biosimilars in rheumatoid arthritis.
    Mok TC, Mok CC.
    Expert Opin Biol Ther; 2024 Jul 20; 24(7):599-613. PubMed ID: 38766765
    [Abstract] [Full Text] [Related]

  • 19. Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.
    Naniwa T, Iwagaitsu S, Kajiura M.
    Int J Rheum Dis; 2018 Mar 20; 21(3):673-687. PubMed ID: 29314738
    [Abstract] [Full Text] [Related]

  • 20. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis.
    Segal B, Rhodus NL, Patel K.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec 20; 106(6):778-87. PubMed ID: 18930662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.